Table 1.

Anti-CD20 bispecific antibodies have encouraging activities. ORR, objective response rate; CR, complete remission

	Study	Indolent NHL		Aggressive B-NHL
		ORR	CR	ORR	CR
bsAbs	Mosunetuzumab Group B	63% N = 67 (2.8–40 mg)	43%	38% N = 98 (2.8–40 mg)	20%
	Regeneron1979	93% N = 14	71%	57% N = 7 (80–160 mg)	57%
	CD20-TCB ≥600 μg	53% N = 70	36%	100% N = 8	100%
CAR-T	JULIET (tisagenlecleucel)	n/a	n/a	50% N = 68	32%
	ZUMA-1 (axicabtagene ciloleucel)	n/a	n/a	73% N = 101	52%

Source: adapted from Dr Budde’s presentation with her permission.